AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Prof David Thomas presents a talk on genomic testing by unlocking the potential of precision oncology for patients and for health systems as part of the ecancer 'Genomics in oncology' series.
He discusses the Cancer Molecular Screening and Therapeutics (MoST) programme and how precision oncology directs benefit.
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours